GLP-1 medication is not right for everyone, and some histories rule it out completely. A few are absolute exclusions, and a longer list calls for careful assessment rather than an automatic no. At TelosRX all of it is screened at intake, and a US-licensed provider makes the decision through asynchronous review.
Four groups should not take it at all. Anyone with a personal or family history of medullary thyroid carcinoma, anyone with multiple endocrine neoplasia type 2, anyone pregnant or breastfeeding, and anyone with a serious prior reaction to this class. Everything else is a conversation with a provider.
Start your intake →The absolute exclusions
These are not judgement calls. If one applies to you, this class of medication is off the table.
A personal history of medullary thyroid carcinoma is an exclusion, and so is a family history of it. The class carries a warning based on thyroid C-cell tumours seen in rodents, and the risk in people cannot be ruled out.
Multiple endocrine neoplasia type 2 is an exclusion for the same reason. It is an inherited syndrome that raises the risk of medullary thyroid carcinoma substantially.
Pregnancy is an exclusion, as is breastfeeding. Weight loss during pregnancy is not the goal, and safety in these situations is not established.
A previous serious allergic or hypersensitivity reaction to a GLP-1 medication is also an exclusion. That history does not get retested.
Pregnancy, breastfeeding and planning
This comes up often enough to deserve its own section, because timing matters.
If you are trying to conceive, tell your provider. Medication is generally stopped well in advance rather than at the moment of a positive test.
If you become pregnant while on treatment, contact your provider promptly. Do not simply stop and say nothing, because the plan around you needs to change too.
Appetite suppression and reduced food intake are not appropriate during pregnancy or while breastfeeding. That is the whole of the reasoning, and it is not negotiable.
Contraception is worth discussing as well, since digestive changes can affect how some oral medication is absorbed.
Key takeaway: A small number of histories are hard exclusions. Most other conditions are not a no, they are a reason for a provider to look more carefully before deciding.
Histories that need careful assessment
These do not rule you out automatically. They do change the conversation, and they must be declared.
- A previous episode of pancreatitis, which needs review before any decision.
- Gallbladder disease or gallstones, since rapid weight change can aggravate both.
- Severe gastrointestinal disease, including gastroparesis and significant reflux.
- Type 1 diabetes, which is managed very differently from type 2.
- Current insulin or sulfonylurea use, because of the risk of low blood sugar.
- Diabetic retinopathy, which can be affected by rapid changes in blood sugar.
- Advanced kidney disease or significant liver disease.
- A current or past eating disorder.
Each of these is common enough that providers see them regularly. None of them is a reason to hide anything at intake.
Why pancreatitis history matters
This is the caution people most often dismiss, and it deserves a proper explanation.
Pancreatitis has been reported with this class of medication, though establishing how often is difficult. Someone who has had it once is generally at higher risk of another episode for reasons unrelated to any drug.
Providers weigh that carefully. Some people with a remote, fully resolved episode may still be candidates, and others will not be.
Regardless of history, everyone taking this medication should know the warning signs. Severe abdominal pain, particularly pain that radiates to the back and does not settle, needs urgent medical assessment.
For background on the condition itself, see the NIH NIDDK overview of pancreatitis.
Eating disorders and this class of medication
This deserves care rather than a policy line, because the interaction is genuinely complicated.
Medication that suppresses appetite can interact badly with a history of restrictive eating. For some people it reinforces patterns that took years to unlearn.
For others, particularly those with a history of binge eating, reduced food noise can be helpful under proper supervision.
The difference is assessment. Tell your provider the full history, including anything treated long ago, and let that inform the decision.
If you are currently in treatment for an eating disorder, involve that clinician. This is not a decision to make in parallel with them.
Diabetes and blood sugar considerations
Type 2 diabetes is not an exclusion. Type 1 is a different matter, and so is your current medication list.
GLP-1 medication alone rarely causes low blood sugar. Combined with insulin or a sulfonylurea, the risk rises meaningfully.
That does not mean you cannot be treated. It means doses of your other medication may need adjusting, and that adjustment belongs to the clinician managing your diabetes.
Tell your provider every medication you take, including anything prescribed elsewhere. Treatment is subject to medical approval by a licensed provider, and the decision depends on the full picture.
Start an online visit and list everything, including doses, so the review is done properly.
Age and general eligibility
Eligibility rests on more than a single number, though weight and weight-related conditions are part of it.
These programmes are for adults. Treatment for younger patients belongs with a specialist rather than an online weight service.
Older adults are not excluded, though frailty, muscle loss and multiple medications all get more weight in the decision.
Your provider confirms eligibility from your intake answers rather than from a rule you can check yourself. Approval is not guaranteed.
Compounded medication is not FDA-approved, which is part of what makes an honest intake so important.
Medication interactions worth flagging
There is no long list of dangerous combinations, but a few things are worth raising.
Because gastric emptying slows, the absorption of some oral medication can change. That matters most for medicines with a narrow margin between too little and too much.
Oral contraception is worth discussing, particularly if you experience vomiting during titration.
Anything requiring careful timing with food deserves a mention, since meal patterns often change considerably in the first weeks.
Supplements count too. List them, including anything sold for weight loss, because some combinations are best avoided.
What happens if you are declined
A decline is the system working. It is worth knowing what it actually involves.
You pay nothing if your application is declined at TelosRX. There is no charge for being screened out.
Sometimes a decline is temporary. A condition that needs assessment first, or a medication that needs adjusting elsewhere, can change the answer later.
Sometimes it is permanent, as with the absolute exclusions. In that case the useful next step is a conversation with your own doctor about other approaches.
Either way, ask why. A reason you understand is more useful than an outcome you resent.
Why honesty at intake protects you
The temptation to shade an answer is understandable, and it is the wrong instinct here.
Screening questions exist because specific histories carry specific risks. Leaving one out does not remove the risk, it removes the person whose job is to manage it.
Partial knowledge is fine. If you are unsure which type of thyroid cancer a relative had, say you are unsure rather than guessing.
Providers can work with uncertainty. They cannot work with a confident wrong answer.
The intake takes about five minutes and is asynchronous, so nobody is waiting on the line while you think. Take the time to get it right.
If you are eligible, what the options look like
For most people none of the exclusions apply, and the question becomes which format suits.
Compounded semaglutide is available as low as $99 a month, and compounded tirzepatide as low as $139 a month.
A microdosed tirzepatide protocol starts as low as $116 a month and uses a gentler curve, which suits people sensitive to side effects. Look at the microdosed protocol.
The needle-free oral GLP-1 is available from $9 a day, dispensing oral semaglutide or oral tirzepatide depending on what your clinician decides. See the needle-free option.
The same exclusions apply to all of them. A lower dose or a different route does not change a contraindication.
Symptoms to act on once you start
Eligibility is the beginning rather than the end of safety. A few symptoms warrant contact regardless of your history.
Severe or persistent abdominal pain, especially pain radiating to the back, needs prompt assessment.
Vomiting that stops you keeping fluids down, or clear signs of dehydration, should not be waited out.
A new neck lump, persistent hoarseness, or difficulty swallowing should be reported and assessed.
So should signs of an allergic reaction, including swelling of the face or throat and difficulty breathing. For background on this class of medication, see the NIH overview of GLP-1 receptor agonists.
Frequently Asked Questions
Who should never take a GLP-1 medication?
Four groups are excluded outright. That means anyone with a personal or family history of medullary thyroid carcinoma, anyone with multiple endocrine neoplasia type 2, and anyone pregnant or breastfeeding. Anyone who has had a serious allergic reaction to this class is also excluded. These are absolute exclusions rather than judgement calls.
Can I take a GLP-1 if I have had pancreatitis?
It requires careful assessment rather than an automatic no. Providers weigh how long ago it happened, what caused it and whether it fully resolved. Everyone taking this medication should know the warning signs of pancreatitis regardless of history.
Does type 2 diabetes rule me out?
No. Type 2 diabetes is not an exclusion. Type 1 is managed very differently, and current insulin or sulfonylurea use raises the risk of low blood sugar, so those medications may need adjusting by the clinician who prescribes them.
What if I have a history of an eating disorder?
Declare it, including anything treated long ago. Appetite-suppressing medication can interact badly with restrictive eating patterns and can be helpful under supervision for others. If you are currently in treatment, involve that clinician in the decision.
Will a lower dose make me eligible?
No. A microdosed protocol or a needle-free oral format does not change a contraindication. The same exclusions apply to every format, because the concern relates to the medication class rather than to the dose or the route.
What happens if I am declined?
You pay nothing. Some declines are temporary and change once a condition is assessed or another medication is adjusted. Others are permanent, in which case your own doctor can discuss weight management approaches outside this class.
TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Not sure where you stand? Message the TelosRX care team or start your evaluation at TelosRX.